Bacteremia or Endocarditis
6-10 mg/kg IV q24h
Skin and Soft Tissue Infections
4 mg/kg IV q24h
Unknown for severe hepatic dysfunction
Bacteremia or endocarditis caused by MRSA or methicillin-resistant coagulase-negative staphylococci in a patient with a serious allergy to vancomycin
Therapy for MRSA infections (other than pneumonia) in which the MIC of vancomycin is ≥2 mcg/mL
Bacteremia or endocarditis caused by MRSA in a patient failing vancomycin therapy defined as:
Salvage therapy for VRE infections other than pneumonia, on a case-by-case basis
Treatment of pneumonia of any kind, as daptomycin is inactivated by pulmonary surfactant.
Initial therapy for Gram-positive infections
VRE colonization of the urine, respiratory tract, wounds, or drains
Convenience due to ease of dosing compared to vancomycin. Clinical pharmacists and/or the Antimicrobial Stewardship Program pharmacists are available to assist with vancomycin dosing.
Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection
Cr weekly (dose adjustment assessment)
Statins and Fibrates: Monitor creatine kinase or hold while on daptomycin therapy (increased myopathy)
Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.
Antimicrobial class: Cyclic lipopeptide. Depolarizes bacterial cell membrane.
Pregnancy category: B
Average serum half life: 9 hours
Urine penetration: Therapeutic
Lung penetration: Poor
CSF penetration: Poor